Get the Stockscreener App
39.12
2.52%
0.96
Harrow Inc stock is traded at $39.12, with a volume of 618.31K.
It is up +2.52% in the last 24 hours and up +8.34% over the past month.
Harrow Inc is an eyecare pharmaceutical company engaged in the discovery, development, and commercialization of ophthalmic pharmaceutical products for the U.S. market. The company helps U.S. eyecare professionals preserve the gift of sight by making its comprehensive portfolio of prescription and non-prescription pharmaceutical products accessible and affordable to millions of Americans. Its operating segments are The Branded segment includes activities of the Company's FDA-approved ophthalmology pharmaceutical products, including the out-licensing of rights to certain of branded products; and The ImprimisRx segment represents activities in the Company's ophthalmology-focused pharmaceutical compounding business.
See More
Previous Close:
$38.16
Open:
$38.36
24h Volume:
618.31K
Relative Volume:
1.26
Market Cap:
$1.45B
Revenue:
$154.15M
Net Income/Loss:
$-33.58M
P/E Ratio:
-40.75
EPS:
-0.96
Net Cash Flow:
$-20.74M
1W Performance:
+0.77%
1M Performance:
+8.34%
6M Performance:
+35.13%
1Y Performance:
-5.32%
1-Day Range:
$38.36
$40.41
1-Week Range:
$36.55
$40.41
52-Week Range:
$20.85
$59.23
Harrow Inc Stock (HROW) Company Profile
Name
Harrow Inc
Sector
Phone
615.733.4731
Address
1A BURTON HILLS BLVD, NASHVILLE, CA
Compare HROW with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
HROW
Harrow Inc
|
39.12 | 1.42B | 154.15M | -33.58M | -20.74M | -0.96 |
|
ZTS
Zoetis Inc
|
156.62 | 67.51B | 9.39B | 2.62B | 2.22B | 5.81 |
|
TAK
Takeda Pharmaceutical Co Adr
|
15.52 | 47.88B | 29.96B | 957.25M | 4.77B | 0.304 |
|
HLN
Haleon Plc Adr
|
9.82 | 43.42B | 14.26B | 1.98B | 2.47B | 0.4347 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
18.46 | 20.72B | 16.70B | -157.13M | 1.19B | -0.155 |
|
UTHR
United Therapeutics Corp
|
312.23 | 14.21B | 2.99B | 1.21B | 1.13B | 25.06 |
Harrow Inc Stock (HROW) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jul-11-25 | Initiated | Cantor Fitzgerald | Overweight |
| Jun-12-25 | Initiated | BTIG Research | Buy |
| Jun-10-25 | Initiated | William Blair | Outperform |
| Feb-06-25 | Initiated | H.C. Wainwright | Buy |
| Dec-04-24 | Reiterated | B. Riley Securities | Buy |
| Apr-11-24 | Initiated | Craig Hallum | Buy |
| Sep-08-22 | Resumed | B. Riley Securities | Buy |
| Oct-14-21 | Resumed | B. Riley Securities | Buy |
| Sep-24-21 | Initiated | Aegis Capital | Buy |
| Jul-02-21 | Initiated | Ladenburg Thalmann | Buy |
View All
Harrow Inc Stock (HROW) Latest News
MACD Cross Could Confirm Trend in Harrow Inc.July 2025 Reactions & Technical Pattern Recognition Alerts - thegnnews.com
Intraday Charts Show Spike in Harrow Inc. ActivityTrade Signal Summary & Proven Capital Preservation Tips - newsimpact.co.kr
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Harrow, Inc. – HROW - FinancialContent
Harrow Second Quarter 2025 Earnings: EPS Beats Expectations, Revenues Lag - Yahoo Finance
Harrow jumps as Cantor initiates with Bullish view on conservative outlook - MSN
What’s the outlook for Harrow Inc.’s sectorPortfolio Risk Summary & AI Powered Trade Plan Recommendations - classian.co.kr
Real time alert setup for Harrow Inc. performance2025 Price Action Summary & Fast Entry Momentum Alerts - Newser
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Harrow, Inc.HROW - cnhinews.com
Best Momentum Stock to Buy for August 15th - MSN
Forecasting Harrow Inc. price range with options data2025 Top Gainers & Daily Volume Surge Signals - Newser
What makes Harrow Inc. stock price move sharply2025 Price Momentum & Long-Term Investment Growth Plans - thegnnews.com
What indicators show strength in Harrow Inc.2025 Dividend Review & Breakout Confirmation Trade Signals - Newser
Surging Earnings Estimates Signal Upside for Harrow (HROW) Stock - Yahoo Finance
Wall Street Analysts Think Harrow (HROW) Could Surge 53.24%: Read This Before Placing a Bet - Yahoo Finance
Can Harrow Inc. deliver consistent EPS growthTrade Signal Summary & Reliable Intraday Trade Alerts - newsyoung.net
Does Harrow Inc. fit your quant trading modelWeekly Profit Analysis & Technical Buy Zone Confirmations - Newser
Byooviz US Launch Slated For 2026 As Harrow Touts Immediate Uptake Potential - insights.citeline.com
Is Harrow's (HROW) Expanding Ophthalmic Pipeline Strengthening Its Long-Term Market Position? - simplywall.st
Harrow's Ambitious Guidance Puts It In The Proving Ground - Seeking Alpha
Momentum Traders Eye Harrow Inc. for Quick BounceWeekly Stock Analysis & Community Trade Idea Sharing - thegnnews.com
Harrow Surprises Market: A New Peak Insight? - timothysykes.com
Harrow, Inc. (HROW) and the Implications of Its Rising Relative Strength Rating: A Sustainable Turnaround in the Ophthalmic Sector? - AInvest
Harrow: Q2 Earnings Snapshot - Local 3 News
Harrow: Exciting Times In Store (NASDAQ:HROW) - Seeking Alpha
Missing your fill of dill without Bick's? Meet Essex County's own longtime pickle packer - CBC
Harrow Health, Inc. (NASDAQ:HROW) Q2 2025 Earnings Call Transcript - Insider Monkey
HROW: HC Wainwright & Co. Raises Price Target, Maintains Buy Rat - GuruFocus
Harrow, Inc. shares rise 2.15% premarket after Q2 2025 earnings call. - AInvest
Harrow Inc (HROW) Q2 2025 Earnings Call Highlights: Revenue Surge and Strategic Expansions By GuruFocus - Investing.com Canada
Harrow Health Reports Strong Q2 2025 Financial Results - TipRanks
Harrow, Inc. shares rise 2.50% after-hours after reporting Q2 earnings that surpassed Wall Street expectations. - AInvest
Harrow, Inc. Q2 2025 Earnings: A Catalyst for Long-Term Ophthalmic Growth - AInvest
Why Harrow Inc. stock attracts strong analyst attentionPowerful ROI Trade Ideas - thegnnews.com
Transcript : Harrow, Inc., Q2 2025 Earnings Call, Aug 12, 2025 - MarketScreener
Harrow, Inc. 2025 Q2ResultsEarnings Call Presentation (NASDAQ:HROW) - Seeking Alpha
A Preview Of Harrow's Earnings - 富途牛牛
Earnings call transcript: Harrow Health beats EPS expectations in Q2 2025 - Investing.com
Harrow Announces Second-Quarter 2025 Financial Results - GlobeNewswire
Harrow Health’s Growth Streak Sets High Hopes For 2025 - Finimize
Harrow Swings to Q2 Earnings, Revenue Jumps - MarketScreener
Earnings Flash (HROW) Harrow, Inc. Posts Q2 Diluted EPS $0.24 per Share - MarketScreener
Earnings Flash (HROW) Harrow, Inc. Reports Q2 Revenue $63.7M, vs. FactSet Est of $66.0M - MarketScreener
Harrow Inc (HROW) Q2 2025: Everything You Need To Know Ahead Of Earnings - Yahoo Finance
Will Harrow's (HROW) Recent Conference Engagements Reveal More About Its Competitive Position? - simplywall.st
Harrow Inc Q2 2025 Earnings Report Preview: Revenue, Earnings, and Price Targets - AInvest
Harrow 8.625% 20260430 HROWL Q2 2025 Earnings Preview Upside Anticipated on Strong Educational Expansion - AInvest
Harrow, Inc. shares fall 1.82% intraday after announcing participation in H.C. Wainwright’s 5th Annual Ophthalmology Conference. - AInvest
Harrow to Present at H.C. Wainwright 5th Annual Ophthalmology Co - GuruFocus
Harrow to Present at H.C. Wainwright 5th Annual Ophthalmology Conference - The Manila Times
Harrow Inc Stock (HROW) Financials Data
Revenue
Net Income
Cash Flow
EPS
Harrow Inc Stock (HROW) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Opaleye Management Inc. | 10% Owner |
Jun 10 '25 |
Sale |
30.80 |
15,000 |
462,033 |
90,000 |
| Opaleye Management Inc. | 10% Owner |
Jun 09 '25 |
Sale |
30.37 |
15,204 |
461,794 |
105,000 |
| Opaleye Management Inc. | 10% Owner |
Jun 03 '25 |
Sale |
30.04 |
3,000 |
90,116 |
122,000 |
| Opaleye Management Inc. | 10% Owner |
Jun 04 '25 |
Sale |
30.02 |
1,796 |
53,907 |
120,204 |
| Opaleye Management Inc. | 10% Owner |
May 12 '25 |
Sale |
25.90 |
10,000 |
258,959 |
130,000 |
| Opaleye Management Inc. | 10% Owner |
May 13 '25 |
Sale |
26.59 |
5,000 |
132,945 |
125,000 |
| BOLL ANDREW R. | Chief Financial Officer |
Apr 03 '25 |
Option Exercise |
0.00 |
346,500 |
0 |
914,589 |
| SAHAREK JOHN P. | CEO & President, ImprimisRx |
Apr 03 '25 |
Option Exercise |
0.00 |
277,200 |
0 |
576,863 |
| BAUM MARK L | Chief Executive Officer |
Apr 03 '25 |
Option Exercise |
0.00 |
762,300 |
0 |
2,899,825 |
| Opaleye Management Inc. | 10% Owner |
Mar 18 '25 |
Sale |
30.01 |
5,000 |
150,055 |
140,000 |
2.37%
0.37%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):